Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy
Author: Shukla, S.D.
Taylor, S.L.
Gibson, P.G.
Barker, D.
Upham, J.W.
Yang, I.A.
Reynolds, P.N.
Hodge, S.
James, A.L.
Rogers, G.B.
Simpson, J.L.
Citation: Thorax, 2021; 76(7):733-736
Publisher: BMJ
Issue Date: 2021
ISSN: 0040-6376
Statement of
Shakti D Shukla, Steven L Taylor, Peter G Gibson, Daniel Barker, John W Upham, Ian A Yang ... et al.
Abstract: Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced <jats:italic>Haemophilus influenzae</jats:italic> load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
Keywords: Sputum
Anti-Bacterial Agents
Prospective Studies
Rights: © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
DOI: 10.1136/thoraxjnl-2020-216331
Grant ID:
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.